Raymond J Henley Iii

Array ( [id] => 17822598 [patent_doc_number] => 11427534 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-08-30 [patent_title] => Solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof [patent_app_type] => utility [patent_app_number] => 17/393144 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 44 [patent_no_of_words] => 56165 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17260050 [patent_doc_number] => 20210373035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => NONINVASIVE METHOD TO QUANTIFY KIDNEY FUNCTION AND FUNCTIONAL DECLINE [patent_app_type] => utility [patent_app_number] => 17/387917 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20385420 [patent_doc_number] => 12485129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Water soluble compositions comprising purified cannabinoids [patent_app_type] => utility [patent_app_number] => 17/387875 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19771 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213007 [patent_doc_number] => 20210346343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE [patent_app_type] => utility [patent_app_number] => 17/381844 [patent_app_country] => US [patent_app_date] => 2021-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17381844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655305 [patent_doc_number] => 20220175770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/381140 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17381140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398097 [patent_doc_number] => 20220040187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/379336 [patent_app_country] => US [patent_app_date] => 2021-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17379336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198541 [patent_doc_number] => 20210338635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => Dosage Regimen for the Treatment of Multiple Sclerosis with a S1P Receptor Modulator [patent_app_type] => utility [patent_app_number] => 17/378052 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626630 [patent_doc_number] => 20230285427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RETT SYNDROME [patent_app_type] => utility [patent_app_number] => 18/006127 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18801511 [patent_doc_number] => 11834663 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Fibrotic treatment [patent_app_type] => utility [patent_app_number] => 17/365260 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 28 [patent_no_of_words] => 30018 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18603391 [patent_doc_number] => 11744831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections [patent_app_type] => utility [patent_app_number] => 17/362103 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 40083 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297776 [patent_doc_number] => 20210393615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND EXPOSURE TO NERVE AGENTS [patent_app_type] => utility [patent_app_number] => 17/360912 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17360912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18443559 [patent_doc_number] => 11679110 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Methods of treating disorders using CSF1R inhibitors [patent_app_type] => utility [patent_app_number] => 17/358137 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 19 [patent_no_of_words] => 122474 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18931019 [patent_doc_number] => 11883413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Inhibition of thymine DNA glycosylase in the treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/358852 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 46 [patent_no_of_words] => 11725 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807307 [patent_doc_number] => 20220259142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => METHODS OF TREATING NEUROFIBROMATOSIS WITH N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE [patent_app_type] => utility [patent_app_number] => 17/357593 [patent_app_country] => US [patent_app_date] => 2021-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179857 [patent_doc_number] => 20230040586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/355813 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17355813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17154837 [patent_doc_number] => 20210315888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION [patent_app_type] => utility [patent_app_number] => 17/304610 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17304610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140086 [patent_doc_number] => 20210308097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS [patent_app_type] => utility [patent_app_number] => 17/352032 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140087 [patent_doc_number] => 20210308098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS [patent_app_type] => utility [patent_app_number] => 17/352071 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201432 [patent_doc_number] => 20240173331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/549916 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7987 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503381 [patent_doc_number] => 20220096483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS [patent_app_type] => utility [patent_app_number] => 17/344777 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17344777 [rel_patent_id] =>[rel_patent_doc_number] =>)